Prognostic factors vary between neoadjuvant and chemo-naïve patients.

Neoadjuvant therapy changes the prognostic landscape for patients with resected pancreatic ductal adenocarcinoma (PDAC). In a study of 2,760 patients, independent predictors of overall survival (OS) differed significantly: chemotherapy-naïve patients were affected by age, CA19-9 levels, and tumor stage, while neoadjuvant therapy patients faced challenges like CA19-9 normalization and nodal presence. These insights led to online personalized prediction tools designed to enhance patient prognostication.